Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 8/20 | 0.40 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387682 | 0.98 | FFAR1 (0.46) | FFAR1SMN1; SMN2MAPTLMNAKDR | |
| SCHEMBL5376634 | 0.96 | FFAR1 (0.47) | FFAR1SMN1; SMN2MAPTLMNAKDR | |
| SCHEMBL5374354 | 0.94 | FFAR1 (0.52) | FFAR1SMN1; SMN2MAPTKDRPPARG | |
| SCHEMBL5381174 | 0.92 | FFAR1 (0.53) | FFAR1MAPTKDRPPARGPPARA | |
| SCHEMBL5376777 | 0.90 | FFAR1 (0.54) | FFAR1SMN1; SMN2MAPTLMNAKDR | |
| SCHEMBL5385603 | 0.89 | PPARG (0.49) | SMN1; SMN2MAPTLMNAPPARGPPARA | |
| SCHEMBL5378957 | 0.89 | TSHR (0.46) | SMN1; SMN2MAPTLMNAPPARGPPARA | |
| SCHEMBL5371978 | 0.88 | FFAR1 (0.57) | FFAR1MAPTKDRPPARGPPARA | |
| SCHEMBL5383071 | 0.87 | KDR (0.56) | FFAR1KDRPPARGPPARA | |
| SCHEMBL5376749 | 0.87 | FFAR1 (0.45) | FFAR1SMN1; SMN2KDRPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179823-B1 | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20050014813-A1 | Process for production of pyrazole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1457490-A1 | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity | Takeda Chemical Industries, Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1445254-A1 | PROCESS FOR PRODUCTION OF PYRAZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-08-11 | — | — | EP | disclosed |
| EP-1228067-B1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-1228067-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGYLCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001038325-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014813-A1 | Process for production of pyrazole compounds | REN, CYP11B1, CYP11B2 | FFAR1 2466/4885SMN1; SMN2 4662/4885MAPT 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.